Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Coming together for the kidneys
January 2020
SHARING OPTIONS:

ST. GALLEN, Switzerland & HAMBURG, Germany—A 50:50 joint venture is underway between Vifor Pharma and Evotec SE that will pursue the discovery and development of novel nephrology therapeutics. Per the agreement, the venture will analyze data from the UK kidney bank NURTuRE to discover new targets. Evotec will apply its drug discovery capabilities, and Vifor’s commercial platform will be similarly leveraged. Once clinical trials are completed for any resulting drugs, the products will be outlicensed to Vifor Pharma for registration and commercialization. Vifor will provide initial funding for preclinical development of €25 million, and Vifor and Evotec will equally share clinical and commercial costs for any successful compounds that result from this deal, with opt-out rights at each stage based on a profit-share agreement.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.